Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information MR PHILIP POWELL BComm (Hons) ACA MAICD Non-Executive Director (appointed 17 June 2019) Mr Powell is a Chartered Accountant with extensive experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is a former Non-Executive Director of RMA Global Ltd (ASX: RMY) (being the only other listed directorship held in the last 3 years), PolyNovo Ltd (ASX: PNV) and Medical Developments International Ltd (ASX: MVP). Mr Powell is the Chair of the Company’s Audit & Risk Committee. MS MARY HARNEY IDP-C INSEAD, BSc, BA (Fine Arts), MAICD FIML Non-Executive Director (appointed 1 October 2024) Ms Harney is an experienced Non-Executive Director and Chief Executive and brings a deep understanding of applied life science research, in addition to experience in biopharmaceutical regulatory affairs and commercialisation. Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. Ms Harney currently serves as Chair of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. Ms Harney was also previously the Chair of Race Oncology (ASX: RAC) (being the only other listed directorship held in the last 3 years), and a former Chair of Microbio Limited. FORMER OFFICEHOLDERS MR DAVID WILLIAMS Non-Executive Chairman (resigned 18 December 2025) Mr Williams is an experienced Director and investment banker with a track record in business development as well as in mergers and acquisitions and capital raising. He has experience advising ASX-listed companies in the food, medical device and pharmaceutical sectors. At the time of his resignation, Mr Williams was Chairman of RMA Global (ASX: RMY) and Managing Director of corporate advisory firm Kidder Williams. In the last 3 years David was also formerly Chairman and Non-Executive Director of PolyNovo (ASX:PNV) and a NonExecutive Director of Medical Developments International Ltd (ASX: MVP). INTERESTS IN THE SHARES AND OPTIONS OF THE COMPANY AND RELATED BODIES CORPORATE As at the date of issuing this report, the interests of the current directors in the shares of the Company were: Ordinary Shares ESS Options Listed Options Mr Peter Gunzburg 3,693,000 – 315,000 Dr Geoffrey Cumming 237,414 250,000 30,000 Mr Max Johnston 990,024 250,000 100,000 Mr Philip Powell 670,344 250,000 30,000 Ms Mary Harney 60,000 250,000 – 17 Annual Report 2026
RkJQdWJsaXNoZXIy MjE2NDg3